82 completed, 2 terminated, 2 unknown, 1 active not recruiting. 55 Phase 3, 19 Phase 2, 12 Phase 4, 2 Not applicable, 1 Phase 1.
By phase and status
Follow Haemophilus Influenzae Type b: new trials by email Literature Review of Haemophilus Influenzae Type b trials Research Report on Haemophilus Influenzae Type b
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Study of BK1803 in Healthy Infants
BK1803, GOBIK Aqueous Suspension Syringes, Bimmugen® Injection - Pertussis, Diphtheria | Phase 3 | Not yet recruiting | Tanabe Pharma Corporation | 344 | 2026-10-01 | 2026-08-28 |
A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series
LBVD, Pentavalent vaccine and Inactivated Polio vaccine - Diphtheria, Tetanus | Phase 2 / Phase 3 | Active not recruiting | LG Chem | 1186 | 2025-05-30 | 2026-09-03 |
The Transparent Safety Study of the 5 in 1 (DTwP-rHepB-Hib) Combination Vaccine Produced by the Indian Serine Institute in Children of Viet Nam Healthy From 6 to 12 Weeks of Age in a 3-dose Regimen, the Interval Between Doses is 4 Weeks
Study subjects will be vaccinated with 3 (three) vaccine doses. The first vaccine will be administered intramuscularly starting at 6-12 weeks of age followed by two doses at four-week interval - Diphtheria, Tetanus | Not applicable | Completed | Vabiotech | 222 | 2018-03-01 | 2019-05-03 |
Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) Administered at 6, 10 and 14 Weeks in Healthy Indian Infants
Infanrix-IPV/Hib - Diphtheria, Acellular Pertussis | Phase 3 | Withdrawn | GlaxoSmithKline | | 2017-12-01 | 2017-12-26 |
Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery
Infanrix hexa - Diphtheria, Hepatitis B | Phase 4 | Completed | GlaxoSmithKline | 551 | 2016-09-19 | 2020-01-14 |
A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia
Infanrix-IPV/Hib - Diphtheria, Tetanus | Phase 3 | Completed | GlaxoSmithKline | 235 | 2016-09-13 | 2019-09-24 |
Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After Birth
Hexaxim® - Diphtheria, Tetanus | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 354 | 2015-04-20 | 2022-04-05 |
Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants
Infanrix hexa, Pediarix, ActHIB - Poliomyelitis, Diphtheria | Phase 3 | Completed | GlaxoSmithKline | 585 | 2014-04-16 | 2019-11-27 |
Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age
Hib-MenCY-TT (MenHibrix®), Pediarix®, Rotarix® - Neisseria Meningitidis, Haemophilus Influenzae Type b | Phase 3 | Completed | GlaxoSmithKline | 600 | 2014-02-01 | 2018-09-14 |
Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination
DTaP-IPV-Hep B- PRP~T + Prevenar + Rotarix vaccine, DTaP- IPV-Hep B-PRP~T + Prevenar + Rotarix + Infanrix hexa vaccine, Infanrix hexa + Prevenar + Rotarix vaccine - Diphtheria, Tetanus | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 558 | 2013-10-01 | 2016-01-05 |
Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and Timeliness in Western Kenya
SMS reminder, Travel subsidy, Travel subsidy 2 - Diphtheria, Tetanus | Not applicable | Completed | Johns Hopkins Bloomberg School of Public Health | 2018 | 2013-10-01 | 2022-10-27 |
Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers
Infanrix-IPV+Hib™ - Acellular Pertussis, Haemophilus Influenzae Type b | Phase 3 | Completed | GlaxoSmithKline | 321 | 2012-12-08 | 2020-01-21 |
Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine
Infanrix hexa™ - Poliomyelitis, Tetanus | Phase 3 | Completed | GlaxoSmithKline | 224 | 2012-04-16 | 2020-01-02 |
Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)
Infanrix hexa, Prevenar 13, GSK217744 - Acellular Pertussis, Hepatitis B | Phase 2 | Completed | GlaxoSmithKline | 657 | 2011-10-14 | 2020-07-17 |
Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine
Infanrix+Hib™, Poliorix™ - Acellular Pertussis, Tetanus | Phase 3 | Completed | GlaxoSmithKline | 831 | 2011-10-01 | 2018-06-06 |
Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™
Blood Sampling - Tetanus, Poliomyelitis | Phase 4 | Completed | GlaxoSmithKline | 58 | 2011-05-30 | 2021-01-19 |
Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine
Infanrix™-IPV+Hib, Infanrix™ IPV, Hiberix™ - Poliomyelitis, Tetanus | Phase 3 | Completed | GlaxoSmithKline | 454 | 2011-03-04 | 2019-11-27 |
Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)
Infanrix hexa™, Prevenar 13®, GSK217744 - Tetanus, Poliomyelitis | Phase 2 | Completed | GlaxoSmithKline | 721 | 2010-12-09 | 2018-08-20 |
Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants.
PENTAXIM™: DTacP IPV//PRP~T combined vaccine, TETRAXIM™: DTacP IPV combined vaccine and ActHIB™: PRP tetanus conjugate vaccine - Diphtheria, Tetanus | Phase 3 | Completed | Sanofi | 370 | 2010-09-01 | 2012-04-17 |
Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose
GSK2202083A vaccine, Infanrix hexa™, Menjugate™ - Tetanus, Diphtheria | Phase 2 | Completed | GlaxoSmithKline | 391 | 2010-08-18 | 2020-01-21 |
Showing 20 of 89. Sign in to see all of them.
Narrower conditions
Haemophilus Infections (89) · Diphtheria (64) · Tetanus (62) · Hepatitis B (49) · Poliomyelitis (40) · Whooping Cough (29) · Measles (2) · Meningococcal Infections (2) · Gram-Negative Bacterial Infections (1) · Influenza, Human (1) · Mumps (1) · Pneumococcal Infections (1) · Rubella (1)
Broader conditions
Bacterial Infections (89) · Bacterial Infections and Mycoses (89) · Infections (89) · Pasteurellaceae Infections (89) · Gram-Negative Bacterial Infections (88) · Actinomycetales Infections (64) · Corynebacterium Infections (64) · Gram-Positive Bacterial Infections (64) · Clostridium Infections (62) · Virus Diseases (62) · Blood-Borne Infections (49) · Communicable Diseases (49) · DNA Virus Infections (49) · Digestive System Diseases (49) · Hepadnaviridae Infections (49)
Interventions
diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (21) · Heptavalent Pneumococcal Conjugate Vaccine (10) · Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate (9) · Hiberix (9) · Vaccines (7) · PEDIARIX (6) · RIX4414 vaccine (6) · Tetanus Toxoid (6) · 13-valent pneumococcal vaccine (5) · DTaP-IPV-HB-PRP-T vaccine (5) · Hib-MenCY-TT vaccine (5) · Diphtheria-Tetanus-acellular Pertussis Vaccines (4) · Haemophilus influenzae-type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine (4) · Pentavac (4) · Chickenpox Vaccine (3)
Sponsors
GlaxoSmithKline (61) · Sanofi Pasteur, a Sanofi Company (10) · Sanofi (5) · Shantha Biotechnics Limited (3) · Novartis Vaccines (2) · Centers for Disease Control and Prevention (1) · Johns Hopkins Bloomberg School of Public Health (1) · LG Chem (1) · Merck Sharp & Dohme LLC (1) · Public Health England (1) · Swedish Institute for Infectious Disease Control (1) · Tanabe Pharma Corporation (1) · Vabiotech (1)
Countries
Philippines (10) · United States (10) · China (8) · Finland (8) · India (6) · Poland (6) · Spain (6) · Thailand (6) · Australia (5) · Germany (4) · Mexico (4) · Sweden (4) · Canada (3) · Dominican Republic (3) · Italy (3)
Top investigators
Raman Rao, MD (3) · Elizabeth Miller, MBBS FRCPath (1) · Eva Netterlid (1) · Rigmor Thorstensson, Assoc. Prof. (1) · Thomas W Hennessy, MD,MPH (1)
Results publications
PMID 17716936, PMID 22327493, PMID 28340322, PMID 17699835, PMID 18463125, PMID 19117896, PMID 20657177, PMID 20950456, PMID 20955461, PMID 21219984, PMID 21289531, PMID 21334243, PMID 21372751, PMID 21807056, PMID 21875633, PMID 22001281, PMID 22531237, PMID 23340564, PMID 23966556, PMID 27145999, PMID 27510380, PMID 28288747, PMID 31307216, PMID 32048889, PMID 33612341
NIH funding
2009 (1), 2014 (1), 2015 (1), 2016 (1)